1. Scrip
  2. >>Therapy Areas
  3. >>Dermatological

Leo's Tralokinumab Poised For US Launch In 2021

 
• By Jessica Merrill

The dermatology specialist said a BLA for the IL-13 blocker has been accepted by the US FDA for the treatment of atopic dermatitis.

SC2007_Second Place_1457882090_1200.jpg
Leo's tralokinumab is poised to be the second biologic to market for atopic dermatitis • Source: Shutterstock

Dermatology specialist LEO Pharma A& is preparing to launch the interleukin-13 inhibitor tralokinumab for atopic dermatitis in the US in 2021, where it will compete against a well-entrenched rival, Sanofi and Regeneron Pharmaceuticals, Inc.'s Dupixent (dupilumab). Leo announced on 9 July that the US Food and Drug Administration has accepted a biologics license application for tralokinumab for the treatment of adults with moderate-to-severe atopic dermatitis, with action expected in the second quarter of 2021.

A regulatory review in Europe is already underway, with an application accepted in June.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Dermatological

Ascletis Plans China Submission After Positive Denifanstat Phase III Acne Results

 
• By Sushmita Panda

Once-daily oral FASN inhibitor denifanstat meets all endpoints in a Chinese Phase III trial for moderate-to-severe acne, paving the way for a regulatory submission in China.

Sanofi Plays It Safer With Blueprint Buy After Bumpy 2025

 
• By Kevin Grogan

But the French major is still keen on early-stage M&A.

InflaRx Stock Sinks As Vilobelimab Fails Phase III Skin Trial

 
• By Kevin Grogan

A study of the German biotech's intravenous complement factor C5a antibody for pyoderma gangrenosum was stopped for futility.

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

More from Therapy Areas

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By Kevin Grogan

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

BioNTech To Buy mRNA Rivals CureVac

 
• By Andrew McConaghie

The $1.25bn buyout is a simple deal for BioNTech, bringing new mRNA R&D and manufacturing capacity while also ending a bothersome patent dispute.

Is Zydus’s Agenus Deal Opportunistic Or Strategic?

 
• By Vibha Ravi

Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?